Avenue Therapeutics Inc
ATXI
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.04M
Close$
$0.20
71.2% downside
Current Fair Value
71.2% downsideOvervalued by 71.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.04 Million |
|---|---|
| Enterprise Value | $100,880.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.93 |
| Beta | -0.17 |
| Outstanding Shares | 3,294,967 |
Return
| Return on Equity | -488.05% |
|---|---|
| Return on Assets | -140.54% |
| Return on Invested Capital | -544.82% |
Valuation & Multiples
| P/E Ratio | -0.73 |
|---|---|
| PEG | 0.24 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.03 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-56.25
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-56.25
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Avenue Therapeutics Inc
Avenue Therapeutics is a specialty pharmaceutical company whose mission is to develop IV tramadol, a potential alternative that could reduce the use of conventional opioids, for patients suffering from acute pain in the U.S. Avenue is he...